1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. RemeGen Co., Ltd.
  6. Company
    9995   CNE1000048G6

REMEGEN CO., LTD.

(9995)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-07-06 am EDT
50.85 HKD   +1.19%
07/05RemeGen Invests $14 Million in Wealth Management Products
MT
05/05RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Director
CI
04/28RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo RemeGen Co., Ltd.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.
Sales per Business
20202021Delta
Biopharmaceutical Research, Service and Production--1 716.10100%-
HKD in Million
Sales per region
20202021Delta
United States--1 557.8590.8%-
China--158.269.2%-
HKD in Million
Managers
Name Title Age Since
Jian Min Fang CEO, Executive Director & Chief Scientific Officer 59 2008
Dao Tian Fu President 58 2019
Jia Li Chief Financial Officer & Joint Secretary 41 2020
Ruyi He Executive Director & Chief Medical Officer 60 2020
Dan Ross Head-Investor Relations - -
Qingkai Wen Joint Secretary 54 2020
Pak Yu Tam Joint Secretary - 2020
Members of the board
Name Title Age Since
Weidong Wang Chairman 61 2019
Xian Jing Hao Independent Non-Executive Director 56 2020
Lan Ma, Dr. Independent Non-Executive Director 63 2021
Yun Jin Chen Independent Non-Executive Director 36 2022
Jian Min Fang CEO, Executive Director & Chief Scientific Officer 59 2008
Ruyi He Executive Director & Chief Medical Officer 60 2020
Jian Lin Executive Director 66 2020
Liqiang Wang, Dr. Non-Executive Director 50 2020
Xiaodi Su, Dr. Non-Executive Director 35 2020
Ren Guangke Member-Supervisory Board 47 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 189,581,239 109,958,333 58.0% 0 0.0% 48.7%
Stock B 1 354,681,764 189,199,934 53.3% 0 0.0%
Stock C 0 70,006,867 0 0.0% 0 0.0%
Shareholders
NameEquities%
Jian Min Fang 59,790,707 31.5%
PAG (Hong Kong) 15,400,762 8.12%
Rc Biology Investment Ltd. 10,818,262 5.71%
E Fund Management Co., Ltd. 9,319,201 4.92%
Weidong Wang 7,572,387 3.99%
The Vanguard Group, Inc. 4,416,864 2.33%
FIL Investment Management (Hong Kong) Ltd. 2,936,500 1.55%
Wellington Management Co. LLP 2,327,659 1.23%
Matthews International Capital Management LLC 2,256,000 1.19%
BlackRock Advisors LLC 2,205,500 1.16%
Brand Portfolio
In partnership withAllbrands.markets
More brands of RemeGen Co., Ltd.